胡夕春 - 复旦大学 - 肿瘤研究所

个人简介

胡夕春教授，主任医师，博士研究生导师，现任复旦大学附属肿瘤医院肿瘤大内科主任，ESMO 国际乳腺癌专家委员会委员，ABC5&6 panelist，中国抗癌协会多原发和不明原发肿瘤专委会主委、中华医学会肿瘤分会肿瘤内科专家委员会副主委、中国研究型医院学会乳腺专委会副主委、国家食品药品监督管理局审评中心审评专家等。主要致力于乳腺癌的内科诊疗，尤其三阴性乳腺癌治疗的优化以及抗肿瘤新药的研发。目前已经发表相关论著200多篇，主编专著9部。作为第一人获得中国抗癌协会科技奖一等奖、全国妇幼健康科学技术奖一等奖和上海市医学科技进步奖一等奖等奖项，上海领军人才，并先后主持国家自然科学基金面上项目、上海市科委项目、十三五“重大新药创制”科技重大专项等。

研究领域

主要致力于乳腺癌的内科诊疗，尤其三阴性乳腺癌治疗的优化以及抗肿瘤新药的研发

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Yu B#, Su J#, Shi Q#, Liu Q, Ma J, Ru G, Zhang L, Zhang J*, Hu X*, Tang J*. KMT5A-methylated SNIP1 promotes triple-negative breast cancer metastasis by activating YAP signaling. Nat Commun. 2022 Apr 21; 13(1):2192. Wang B#, Zhao Y#, Li Y#, Xu Y#, Chen Y, Jiang Q, Yao D, Zhang L, Hu X*, Fu C*, Zhang S*, Chen S*. A plasma SNORD33 signature predicts platinum benefit in metastatic triple-negative breast cancer patients. Mol Cancer. 2022 Jan 18; 21(1):22. Xie Y#, Wang B#, Zhao Y, Tao Z, Wang Y, Chen G*, Hu X*. Mammary adipocytes protect triple-negative breast cancer cells from ferroptosis. J Hematol Oncol. 2022 Jun 3; 15(1):72. Zhang J#, Ji D#, Cai L, Yao H, Yan M, Wang X, Shen W, Du Y, Pang H, Lai X, Zeng H, Huang J, Sun Y, Peng X, Xu J, Yang J, Yang F, Xu T, Hu X*. First-in-human HER2-targeted Bispecific Antibody KN026 for the Treatment of Patients with HER2-positive Metastatic Breast Cancer: Results from a Phase I Study. Clin Cancer Res. 2022 Feb 15; 28(4):618-628. Zhang J#, Ji D#, Shen W#, Xiao Q, Gu Y, O'Shaughnessy J, Hu X*. Phase I Trial of a Novel Anti-HER2 Antibody-drug Conjugate, ARX788, for the Treatment of HER2-positive Metastatic Breast Cancer. Clin Cancer Res. 2022 May 26:clincanres.0456.2022-2-11 09:49:17.170. Zhang QY#, Sun T#, Yin YM#, Li HP#, Yan M, Tong ZS, Oppermann CP, Liu YP, Costa R, Li M, Cheng Y, Ouyang QC, Chen X, Liao N, Wu XH, Wang XJ, Feng JF, Hegg R, Kanakasetty GB, Coccia-Portugal MA, Han RB, Lu Y, Chi HD, Jiang ZF*, Hu XC*. MONARCH plus: abemaciclib plus endocrine therapy in women with HR+/HER2- advanced breast cancer: the multinational randomized phase III study. Ther Adv Med Oncol. 2020 Oct 22; 12:1758835920963925. Yuan P#, Hu X#, Sun T, Li W, Zhang Q, Cui S, Cheng Y, Ouyang Q, Wang X, Chen Z, Hiraiwa M, Saito K, Funasaka S, Xu B*. Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial. Eur J Cancer. 2019 May; 112:57-65. Zhang J#, Lin Y#, Sun XJ, Wang BY, Wang ZH, Luo JF, Wang LP, Zhang S, Cao J, Tao ZH, Wu J, Shao ZM, Yang WT, Hu XC*. Biomarker assessment of the CBCSG006 trial: A randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer. Ann Oncol. 2018 Aug 1; 29(8):1741-1747. Zhang S#, Liang F#, Li W, Hu X*. Subgroup Analyses in Reporting of Phase III Clinical Trials in Solid Tumors. J Clin Oncol. 2015 May 20; 33(15):1697-702. Hu XC#*, Zhang J#, Xu BH, Cai L, Ragaz J, Wang ZH, Wang BY, Teng YE, Tong ZS, Pan YY, Yin YM, Wu CP, Jiang ZF, Wang XJ, Lou GY, Liu DG, Feng JF, Luo JF, Sun K, Gu YJ, Wu J, Shao ZM. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2015 Apr; 16(4):436-46.